AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9859533
Drug: Cefotetan 2
RxNorm normalized name: cefotetan 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 2 x 1 g (43 subjects)
Trial: 9859533
Drug: Cefalotin 3
RxNorm normalized name: Céfalotine
DrugBank: Cefalotin (DB00456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefalotin 3 x 2 g for 24 hours (27 subjects)
Trial: 9859533
Drug: Cefalotin 3
RxNorm normalized name: Céfalotine
DrugBank: Cefalotin (DB00456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefalotin 3 x 2 g for 72 hours (41 subjects)
Trial: 7881264
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CyA) mouthwash, 5 ml solution at 10% in olive oil, used for five minutes, three times a day for eight weeks.
Trial: 7881264
Drug: Acetonide of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetonide of triamcinolone 01% in aqueous solution (control group).
Trial: 1983349
Drug: Intravenous pentagastrin
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentagastrin (0.6 microgram.kg/h) with placebo
Trial: 1983349
Drug: Intravenous pentagastrin
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentagastrin (0.6 microgram.kg/h) with ranitidine 300 mg
Trial: 530855
Drug: One-step treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step treatment
Trial: 530855
Drug: Planned interval
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Planned interval treatment
Trial: 24368466
Drug: Diflunisal, 250
RxNorm normalized name: Diflunisal, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal, 250 mg twice daily for 2 years
Trial: 24368466
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 2 years
Trial: 21807773
Drug: Intravenous slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous slow 5 IU oxytocin bolus over 1 minute and additional 40 IU oxytocin infusion in 500 mL of 0.9% saline solution over 4 hours (bolus and infusion)
Trial: 21807773
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU oxytocin bolus over 1 minute and 500 mL of 0.9% saline solution over 4 hours (placebo infusion) (bolus only)
Trial: 19102515
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 or 40 mg/day
Trial: 19102515
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 or 40 mg/day with or without hydrochlorothiazide
Trial: 16883966
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation (0.625 mg/day)
Trial: 16883966
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin compound supplementation (riboflavin 0.625 mg/day, thiamin 0.512 mg/day, nicotinic acid 0.365 mg/day, folic acid 0.13 mg/day)
Trial: 9469527
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release morphine
Trial: 8184813
Drug: Lisinopril 5
RxNorm normalized name: lisinopril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5 mg (target 20 mg)/day (n = 20)
Trial: 3309233
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (30 to 40 mg/kg/24 hr)
Trial: 31964660
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy with standard podiatry care over 24 weeks
Trial: 29535130
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus 9 weeks of trastuzumab
Trial: 29535130
Drug: Combined analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined analysis of both treatment arms
Trial: 24157957
Drug: Aleglitazar plus
RxNorm normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleglitazar plus single-dose warfarin
Trial: 20418072
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/day for 3 weeks
Trial: 18714059
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg) plus vitamin B(12) (0.4 mg)
Trial: 12507972
Drug: Vitamin B(6)
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B(6) (40 mg)
Trial: 10339732
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - Beclomethasone dipropionate (BDP) 0.4 mg/day
Trial: 2117204
Drug: Curosurf (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curosurf (200 mg/kg)
Trial: 323793
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza A vaccine administered intranasally
Trial: 323793
Drug: Killed subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed subunit vaccine
Trial: 323793
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza A vaccine
Trial: 323793
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza A vaccine and Killed subunit vaccine
Trial: 31625653
Drug: Adapted antibiotic
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted antibiotic stewardship intervention
Trial: 30879569
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 PUFAs (2.6 g daily)
Trial: 24840781
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate 6 g/day
Trial: 24840781
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate 4 g/day
Trial: 24800383
Drug: Email-linked website
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Email-linked website intervention with ten consecutive weekly emails and two motivational phone calls
Trial: 17019594
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg/day for 2 weeks)
Trial: 10211008
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 21, 12 and 6 mg kg‐1 h‐1 for a minimum of 2 hours
Trial: 10150182
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg b.i.d., oral)
Trial: 3127417
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified FSH (225 IU daily for 10 days)
Trial: 3127417
Drug: Human menopausal
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human menopausal gonadotropin (hMG; 225 IU daily for 10 days)
Trial: 30277639
Drug: ABVE-PC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVE-PC chemotherapy followed by response evaluation
Trial: 30277639
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiotherapy (IFRT) or no further therapy for RERs with CR
Trial: 28855976
Drug: Hydroxytyrosol (HT)
DrugBank: Hydroxytyrosol (DB12771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxytyrosol (HT) 15 mg/day for 3 weeks
Trial: 26547357
Drug: Vericiguat 10
RxNorm normalized name: vericiguat 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 10 mg
Trial: 26547357
Drug: Pooled vericiguat
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pooled vericiguat groups (1.25 mg, 2.5 mg, 5 mg, 10 mg)
Trial: 26547357
Drug: Vericiguat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (various doses)
Trial: 23568622
Drug: 1-carbamimidoyl-L-proline (CLP)
RxNorm normalized name: CYPERUS PROLIFER WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-carbamimidoyl-L-proline (CLP)
Trial: 19062477
Drug: Manix 600
RxNorm normalized name: witch hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manix 600 mg for 13 weeks
Trial: 9386082
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) - 10 mg infused in 500 mL of normal saline
Trial: 9386082
Drug: Aprotinin (AP)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (AP) - High-dose: 280 mg loading dose, 280 mg in CPB prime solution, 70 mg/h for 6 hours
Trial: 3203055
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg rectally as premedication
Trial: 30666023
Drug: Home-based follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based follow-up care (HBFC) intervention administered for 12 months
Trial: 28926762
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (200mg twice daily)
Trial: 24498826
Drug: Isotretinoin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (0.5 mg/kg/day) + Vitamin E (800 IU/day)
Trial: 24498826
Drug: Isotretinoin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (0.5 mg/kg/day) + Cod liver oil (800 IU/day)
Trial: 22028471
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents or bare metal stents
Trial: 19252250
Drug: Disease modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease modifying anti-rheumatic drugs (DMARDs), specifically methotrexate (MTX) as the anchor drug.
Trial: 19252250
Drug: Disease modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease modifying anti-rheumatic drugs (DMARDs)
Trial: 9602764
Drug: ibuprofen for
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen for 3 weeks
Trial: 9602764
Drug: ibuprofen for
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen for 1 week and placebo for the next 2 weeks
Trial: 8042206
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GM-1 followed by 100 mg GM-1 daily for 10 days and 100 mg GM-1 intramuscularly for 11-21 days
Trial: 3281620
Drug: Diuretic-metoprolol combination
RxNorm normalized name: metoprolol and other diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic-metoprolol combination therapy
Trial: 3281620
Drug: High-dose diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose diuretic therapy (100 to 150 mg/d of hydrochlorothiazide)
Trial: 29084488
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for depression
Trial: 28746222
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg in 5 mL normal saline (NS)
Trial: 18582177
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 to 3.5 mg/day)
Trial: 10831925
Drug: Matrix transdermal
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix transdermal 17beta‐estradiol patch
Trial: 8991327
Drug: Victimization experiences
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Victimization experiences (e.g., sexual abuse, parental assault, kidnapping)
Trial: 6202963
Drug: Felodipine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 12.5 mg t.i.d. for 3 days
Trial: 6202963
Drug: Felodipine 25
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 25 mg t.i.d. for 3 days
Trial: 6202963
Drug: Felodipine 50
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 50 mg t.i.d. for 3 days
Trial: 18317718
Drug: BCG-RIVM 2x10^8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-RIVM 2x10^8 CFU in six weekly instillations
Trial: 18317718
Drug: MMC 20
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC 20 mg in six weekly instillations
Trial: 18317718
Drug: MMC 20
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC 20 mg in six weekly instillations with subsequent monthly instillations for 3 years
Trial: 18317718
Drug: MMC 20
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC 20 mg instilled weekly six times
Trial: 12808486
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg daily) added after 12 weeks
Trial: 8897119
Drug: Dexamethasone (DEX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (DEX), 0.5 mg at night
Trial: 1740677
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy (CHT)
Trial: 31520525
Drug: Triheptanoin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triheptanoin (1 g/kg/day)
Trial: 30064968
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group who tried the intervention
Trial: 25755685
Drug: 9.5 mg/24
RxNorm normalized name: Exelon, 9.5 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.5 mg/24 h rivastigmine patch
Trial: 18041917
Drug: Higher total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher total doses of radiation (1.8-2 Gy)
Trial: 18041917
Drug: Hypofractionated regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated regimens (larger daily doses)
Trial: 18041917
Drug: Conventional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional daily doses (1.8-2 Gy)
Trial: 8607589
Drug: Warfarin (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted dose, INR 2.0 to 3.0)
Trial: 2990711
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor (TF) immunotherapy for 18 months in addition to radiotherapy
Trial: 30328496
Drug: Posterior-Stabilized (PS)
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior-Stabilized (PS) implants
Trial: 30328496
Drug: Medially Congruent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medially Congruent (MC) implants
Trial: 22173281
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (37.5 mg/day for 4 days, then 75 mg/day for 6 days)
Trial: 22173281
Drug: Desvenlafaxine XR
RxNorm normalized name: desvenlafaxine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine XR (50 mg/day for 10 days)
Trial: 22173281
Drug: Indinavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (800 mg) co-administered on day 12
Trial: 10190404
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with metoprolol + felodipine
Trial: 10190404
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with enalaril + hydrochlorothiazide
Trial: 2367393
Drug: Ofloxacin 2
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 2 X 200 mg orally for 10 days
Trial: 2367393
Drug: Established antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established antibiotics
Trial: 28232290
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement and cognitive behavioral therapy intervention (MET/CBT-7)
Trial: 15174325
Drug: Mexicor (6-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for unstable angina (UA)
Trial: 15174325
Drug: Mexicor (6-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for acute myocardial infarction (MI)
Trial: 15174325
Drug: Mexicor (6-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for hypertensive crises (HC)
Trial: 15174325
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone for unstable angina (UA)
Trial: 15174325
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone for acute myocardial infarction (MI)
Trial: 15174325
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone for hypertensive crises (HC)
Trial: 11697832
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg/m2, days 1, 8 and 15
Trial: 11697832
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2, day 1) plus Vindesine (3 mg/m2, days 1 and 15) (PV)
Trial: 20845288
Drug: Intramuscular tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tramadol 100 mg
Trial: 7517825
Drug: Intramuscular tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tramadol 300 mg
Trial: 31901710
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (50,000 IU weekly for 8 weeks)
Trial: 28382551
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C + 235 mg vitamin E daily (AO)
Trial: 25719419
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone associated with hyaluronic acid (group 3)
Trial: 25719419
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone (group 2)
Trial: 18986534
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg licofelone twice daily
Trial: 6373158
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen twice daily
Trial: 17034279
Drug: Guideline standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline standard therapy
Trial: 12514268
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of psyllium per day for 30 days
Trial: 12514268
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of psyllium per day for 30 days (control)
Trial: 10882617
Drug: PRO 542
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRO 542 (0.2-10 mg/kg)
Trial: 8891083
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg for the first week, 40 mg for the remaining period)
Trial: 1799283
Drug: Fructose alone
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose alone (50 g)
Trial: 1799283
Drug: Glucose alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose alone (50 g)
Trial: 1799283
Drug: Fructose plus
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose plus starch (50 g fructose + 15 g starch)
Trial: 23059357
Drug: Single 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 0.5 mL dose of virosomal subunit influenza vaccine (Inflexal V)